Purchase this article with an account.
S. K. Patel, J. Heffez, P. E. Carvounis, A. C. Kopel, E. R. Holz; Nepafenac 0.1% for the Treatment of Cystoid Macular Edema. Invest. Ophthalmol. Vis. Sci. 2008;49(13):5628.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the short term visual outcomes following use of Nepafenac 0.1% for postoperative and uveitic cystoid macular edema (CME).
Retrospective, comparative study of 18 eyes of 17 patients with CME who were treated with nepafenac 0.1%. The primary outcome was visual acuity 6 weeks after initiation of treatment.
There were 6 eyes with CME following cataract surgery treated with nevanac 1-5 months after surgery (mean 3.3 months): mean log MAR visual acuity improved from 0.68 (20/95) to 0.42 (20/53) which was highly statistically significant (p=0.0003). There were 9 eyes of 9 patients with CME following surgery other than cataract surgery: mean log MAR visual acuity was 0.83 (20/136) at baseline and worsened to 0.85 (20/143, p=0.85). In the 3 eyes with uveitic CME vision was 0.22 (20/34) at baseline and was 0.41 (20/52) after 6 weeks of nepafenac treatment (p=0.29).
There is significant improvement in visual acuity following nepafenac treatment of CME related to cataract surgery although this may not be superior to that expected by natural history. Six week results of nepafenac treatment for CME secondary to uveitis or surgery other than cataract surgery are disappointing.
This PDF is available to Subscribers Only